ALLTERUM

Allterum Therapeutics, Inc.

Advancing the Next Generation of Best-In-Class Precision Oncology and Inflammation Therapeutics

- Phase 1 First-In-Human Trial is Enrolling Patients
- Program is Fully Funded Through Phase 2a in ALL
- Series Seed 2 Completed in 2Q26
- Series A Planned in 2027

www.allterum.com

FANNIN
A Fannin-Established Company

4A10: Strategic Development Path to Solve the High Unmet Need in R/R ALL

4A10 DEVELOPMENT PATH

1. Discovered by Dr. Scott Durum at NCI
2. 2020: In-licensed
3. 1H 2025: IND-enabling completed
4. 3Q 2025: IND filed and cleared
5. 2Q 2026: Planned entry into clinic

WHAT CRITICAL PROBLEM IS 4A10 SOLVING?

High clinical unmet need

- 5-year overall survival <50%
- Lack of good alternative therapies for relapsing or refractory patients

<50%

5-year survival

Regulatory opportunity

- Orphan designation
- Fast Track designation
- PRV (Pediatric Review Voucher) eligible

R/R ALL Represents a High-Value First Indication for 4A10

4A10: Best-In-Class Anti-CD127 Therapy

Clinically Validated Target	Robust In-Vivo Efficacy	No Binding to Normal Tissues	Well Tolerated vs. Previous IL-7i	No Evidence of a Cytokine Storm



Triple Mechanism of Action



Robust Efficacy Data Package Supported Transition To The Clinic

CD127 is Highly Expressed on ETP[1] T-ALL and 4A10 Mediates ADCC[2]

CD127 Expression in Patient Derived ETP T-ALL Cells



CD127 expression (blue) indicated by increased MFI readout via flow cytometry

4A10 Induces ADCC in ETP T-ALL Models



Increasing the ratio of effector to target (E:T) cells correlates with increased 4A10-induced ADCC

[1] ETP = Early T-cell Precursor ALL; associated with poor response to treatment and poor outcomes
[2] Data from Durum Lab (unpublished)

CD127 is Highly Expressed in B-ALL Cell Lines, 4A10 Mediates ADCC

4A10 Binds CD127 and Induces ADCC In Multiple B-ALL Cell Lines[1,2,3]



[1] 4A10 detects and binds CD127 similarly to commercial Anti-CD127 used in flow cytometry
[2] Data from Durum Lab (unpublished)
[3] Increasing the ratio of effector to target (E:T) cells correlates with increased 4A10-induced ADCC

4A10: In Vivo Efficacy in T-ALL & B-ALL (PDX models)

4A10 Treatment Reduced T-ALL Leukemic Burden in BM



Note: NCCN criteria for morphologic complete remission (CR) includes <5% lymphoblasts in patient marrow[2].

4A10 Significantly Delayed Leukemia Growth In ETP T-ALL PDXs



4A10 Significantly Increased Survival in Mice with T-ALL



Note: 4A10 in-vivo activity was comparable to that reported for blinatumomab (Blincyto), an Amgen BiTE targeting CD19/CD3 approved for R/R B-ALL

4A10 Enhanced Survival In Mice with ETP T-ALL



Post Treatment Initiation (4A10 Treatment through D45)

4A10 Anticancer Activity in 5 Different B-ALL Subtype PDX Models[1,2]



[1] For each model, mice were treated once/week with 4A10 after establishing leukemia
[2] Data from Baldrini Institute (Priscila Zenatti, unpublished)

Favorable Safety Profile

No 4A10-associated safety signals

In multiple species, including NOAEL[1] at MFD[2] in NHPs[3] (GLP tox)

Minimum 4A10 binding to normal tissue observed

In a GLP tissue cross-reactivity study

No evidence of "Cytokine Storm"

In human PBMCs[4] treated with 4A10

Binds CD127 with high selectivity and high affinity

Consistent with published data

Significant External Validation

- Key data reproduced by multiple collaborators
- Program endorsed by prominent US leukemia investigators
- FDA Orphan Drug & Fast Track Designations
- Received four competitive, peer-reviewed grants (NCI[6] x 1, CPRIT[7] x 3)
- Accepted into the NCI NExT[8] & PIVOT[9] Programs
- Pediatric Rare Disease Voucher Eligibility

[1]NOAEL = No Observed Adverse Event Level
[2]MFD= Maximum feasible dose
[3]NHPs = Non human primates
[4]PBMCs = Pluri-potent bone marrow cells
[5]NCI = National Cancer Institute
[6]CPRIT = Cancer Prevention and Research Institute of Texas
[7]NExT = NCI experimental therapeutics
[8]PIVOT = NCI pediatric preclinical in-vivo testing

Substantial Derisking Efforts in Early Development with Non-Dilutive Capital

Key Development Milestones

4A10 In-Licensed from National Cancer Institute (NCI)

Orphan Drug Designation

Pediatric Rare Disease Designation (PRV Eligible)

Robust animal data package generated with leading academic centers

GLP Tox studies (NHPs) suggests favorable tolerability in patients

FDA cleared IND allowing initiation of First-In-Human clinical trials

Fast Track designation

$24M
in grant funding to-date

$6.0M
in equity financing to-date

~75% of funding to-date is non-dilutive to shareholders



Timeline to Entering the Clinic



Program Endorsed by Prominent Leukemia Investigators

IND Cleared by FDA

First Clinical Trial Sites Initiated

Transition To The Clinic Activities

- Key Endorsements Received
- Study Protocol Approved by FDA
- Study Infrastructure In-Place
- IRB Approvals
- Study and Site Initiation Activities
- Key Management Hirings

SEED 2 + CPRIT/NCI Grants: Funds T/B-ALL Through Phase 2a

~$14.5M in funding is required to complete phase 1/2a clinical trials in T/B-ALL

- $5.5M – Remaining funds in CPRIT grant
- $5M – SEED 2 financing
- $1M – NCI SBIR grant awarded 3Q25
- $3M – CPRIT supplemental grant awarded 2Q25

Intended Use of Proceeds*

- ~ $5.0M - Phase 1 Clinical Trial
- ~ $2.0M - Phase 2a T-ALL Clinical Trial
- ~ $3.0M - Phase 2a B-ALL Clinical Trial
- ~ $0.6M - Pipeline Expansion activities
- ~ $3.4M - G&A
- ~ $0.5M - Runway

Calculation is based on $100K /patient cost

SEED 2 Round Closed in 2Q26

Initial Commercialization Opportunity in ~ 24mo



STRATEGIC DERISKING WITH NON-DILUTIVE CAPITAL



NIH National Cancer Institute · PIVOT Pediatric Preclinical In Vivo Testing · National Cancer Institute · The University of Texas MD Anderson Cancer Center Making Cancer History · CPRIT Cancer Prevention & Research Institute of Texas · FDA Priority Review · Boldrini · Texas Children's Hospital · Children's Hospital of Philadelphia · Baylor College of Medicine · Catalyst Clinical Research

[1] R/R T/B-ALL/LL = Relapsed / Refractory T-cell or pre-B-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
[2] AML= Acute Myeloid Leukemia
[3] NHL= Non-Hodgkin Lymphoma
[4] CRC= Colorectal Cancer

Completed · In Progress / Future Trial

Significant Untapped Commercial Opportunity In Combinations

Annual Revenues of Drugs Approved Downstream of IL-7

~$1.4B
VONJO (pacritinib) capsules

~$2.7B
Jakafi ruxolitinib tablets

~$2.5B
VENCLEXTA venetoclax tablets

~$2B
Tafinlar

A Myriad of Validated Signaling Pathways Downstream of IL-7



4A10 is Attractive in Combinations: Improves Efficacy, No Added Toxicity

A World Class Leadership Team

Yan Moore, MD, MBA
Chief Executive Officer
BMS, GE Healthcare, GSK, Sanofi
Ariad, GPC Biotech, IPSEN, Omega
TAU, Drexel U, HBS, LBS
https://www.linkedin.com/in/yan-moore-md-mba-4386862/

Mark Worscheh, MBA
Chief Financial Officer
Fannin Partners, Aquinas Co's
NatWest, Merrill Lynch, Salomon Brothers
Notre Damm U, Stanford GSB
https://www.linkedin.com/in/mark-worscheh-387b3b/

Philip P. Breitfeld, MD
Chief Medical Officer
Merck KGaA, Quintiles, IQVIA
HMS, UMass, Princeton U
https://www.linkedin.com/in/philip-p-breitfeld-md-b429526/

Atul Varadhachary, MD, PhD
President R&D
McKinsey, Agennix, Reliance Life Sciences
Mumbai U, John's Hopkins U
https://www.linkedin.com/in/varadhachary/

John "Jack" Schaumberg, PhD
Head, Clinical Operations
Pulmotect, Agennix, PRA,
Pfizer, GSK
https://www.linkedin.com/in/jack-schaumberg-6a2a0911/

Shibani Kudchadkar, MD, ACRP-CP
Associate Medical Director,
Clinical Development & Operations
Krystal Biotech, Jeune Aesthetics
ICON plc, Johns Hopkins U, Penn State COM
https://www.linkedin.com/in/shibanikudchadkar-a490241aa/

Brian Wipke, PhD
VP, Research & Development
Manifold Bio, Moderna, Biogen, Elan Pharmaceuticals
University of Washington, University of California Berkeley
https://www.linkedin.com/in/brianwipke

Ross H. Clary, BSc
Dir. Investor Relations
Fannin
Texas A&M
https://www.linkedin.com/in/rossclary/

Michael J. Heffernan, PhD
Head, Quality & Technical Operations
Duke U, Baylor, Georgia Tech
Virginia Tech
https://www.linkedin.com/in/mjheffernan/

Stephanie Vega, PhD
Sr. R&D Manager,
Non-Clinical Development
UTMB, Fannin, Raptamere Therapeutics
https://www.linkedin.com/in/stephaniepvega/

Uksha Saini, PhD
Sr. Discovery Scientist, R&D
Fannin
IHBT, Ohio State U
https://www.linkedin.com/in/uksha-saini-449b42aa/

Morgan Benson, ACRP-CP
Program Associate
Bellicum, Kiromic (Immunocell)
https://www.linkedin.com/in/morgan-benson-clinops/

Justine Delgado, PhD
Clinical Trial Manager
Beckman Coulter, Salarius Iterion, March Biosciences, Univ. of Iowa
www.linkedin.com/in/justine-delgado-08219

Board of Directors

Atul Varadhachary, MD, PhD
Exec. Chair, Board of Directors
McKinsey, Agennix, Reliance Life Sciences
Mumbai U, John's Hopkins U
https://www.linkedin.com/in/varadhachary/

Leo Linbeck, III, MBA
Member, Board of Directors
CEO Aquinas Co's
Lecturer in Management @ Stanford GSB
https://www.linkedin.com/in/leo-linbeck-88482127/

Mark Worscheh, MBA
Member, Board of Directors
Fannin Partners, Aquinas Co's
NatWest, Merrill Lynch, Salomon Brothers
Notre Damm U, Stanford GSB
https://www.linkedin.com/in/mark-worscheh-387b3b/

Yan Moore, MD, MBA
CEO & Member, Board of Directors
BMS, GE Healthcare, GSK, Sanofi
Ariad, GPC Biotech, IPSEN, Omega
TAU, Drexel U, HBS, LBS
https://www.linkedin.com/in/yan-moore-md-mba-4386862/

Scientific Advisors / Collaborators

Scott Durum, PhD

- 4A10 Lead Inventor
- Senior PI (NCI) and Head, Cytokines & Immunity
- >25 years of IL-7 research

Eric Schafer, MD, MHS

- Associate Professor, Hematology/ Oncology at Baylor College and Texas Children's Hospital
- Member of Children's Oncology Group and TACL

Susan Rheingold, MD

- Professor of Pediatrics at University of Pennsylvania
- Medical Director, Outpatient Oncology at CHOP

Elias Jabbour, MD

- Professor, Leukemia, at MD Anderson Cancer Center
- Lead 4A10 investigator for adult ALL patients

Sarah K. Tasian, MD

- Chief, Hematologic Malignancies Program at CHOP
- Development of molecularly-targeted therapeutics for children with high-risk leukemias

Andres Yunes, PhD

- Investigator, Leukemia, Boldrini Research Center (Brazil)
- Genetic testing and PDX models of T- and B-ALL.

Priscila Zenatti, PhD

- Investigator, Leukemia, Boldrini Research Center
- Pediatric leukemia therapeutics & murine models

Richard Gorlick, MD

- Division Head, Division of Pediatrics at MDACC
- Study Chair for 4A10 osteosarcoma PDXs in partnership with NCI PIVOT program

Branko Cuglievan, MD

- Section Chief, Pediatric Hematological Malignancies
- The University of Texas MD Anderson Cancer Center and Children's Memorial Hermann

Developmental Partners

NCI Experimental Therapeutics (NExT) Program

Providing support for toxicology studies and GMP manufacturing

- **Rosemarie Aurigemma, PhD**: Associate Director, Developmental Therapeutics Program
- **Jason Yovandich, PhD**: Chief, Biological Resources Branch (BRB)
- **Kasia Bourcier, PhD**: Program Director, BRB
- **Elizabeth Glaze, PhD, DABT**: Chief, Toxicology and Pharmacology Branch (TPB)

Prominent Leukemia & Lymphoma Collaborating Investigators

- **Eric Schafer, MD, MHS**
- **Susan Rheingold, MD**
- **Elias Jabbour, MD**
- **Branko Cuglievan, MD**

Lead NCI Inventor & Scientific Expert

- **Scot Durum, PhD**

NCI Preclinical in Vivo Testing (PIVOT) Program

Testing 4A10 efficacy in osteosarcoma PDX models; partnered with MDACC and Jackson Labs

National Cancer Institute · Children's Hospital of Philadelphia · Baylor College of Medicine · Texas Children's Hospital · Catalyst Clinical Research · FUJIFILM Diosynth biotechnologies · The University of Texas MD Anderson Cancer Center · Boldrini · PPD

SUMMARY

The Allterum Journey to Value Creation

2025

- **1Q25:** First dose series SEED 2
- **3Q25:** IND clearance
- **3Q25:** $3M (CPRIT), $1M (NCI SBIR) awarded
- **4Q25:** FDA Orphan & Fast Track Designations

2026

- **2Q26:** Initiate phase 1 first-in-human (FPI)
- **2Q26:** Final close of SEED 2
- Initiate additional 4A10 clinical programs
- Initiate IND enabling studies for pipeline asset(s)

2027

- Phase 1 in ALL data readout
- Initiate Phase 2a in ALL
- Potential FDA accelerated approval conversation
- Multiple phase 2a trials for additional hematology-oncology programs
- Enter the clinic with pipeline assets

Best-in-Class Anti-CD127: Triple MoA

- Highly Selective & No Off-Target Toxicity
- FDA Fast Track & Orphan Designations, Abbreviated Path to Approval
- Eligible for a Pediatric Review Voucher (PRV)
- Fully Funded Through Phase 2a Completion in ALL

>$1B Market Potential - ALL & 5+ Indication Expansion

- $24M in Non-Dilutive Capital (NCI & CPRIT grants); De-Risked, Validated Science
- Single Agent Activity Across Hematology, Autoimmune Disorders & Solid Tumors
- Combination Synergy with Approved Drugs; Improved Efficacy, No Added Toxicity

Diversified First-In-Class Pipeline

- RapDC-CD127
- RapDC-LY6D
- TAE (BST-12)

The Company is Led by a Bio-Pharma Veteran CEO with a Proven Drug Development Track Record

ALLTERUM

Thank you!

ymoore@allterum.com

FANNIN
A Fannin-Established Company